Glipizide
From SNPedia
Glipizide, primarily marketed in the US by Pfizer under the trade name Glucotrol, is an oral rapid- and short-acting anti-diabetic medication from the sulfonylurea class. It is classified as a second-generation sulfonylurea, which means that it undergoes enterohepatic circulation. Second-generation sulfonylureas are both more potent and have shorter half-lives than the first-generation sulfonylureas.Wikipedia
The US FDA includes a precautionary warning on Glipizide/Glucotrol for individuals with G6PD deficiencies due to the risk for hemolytic anemia, and non-sulfonylurea alternatives should be considered.[1]
| Genotype/Genoset | Diplotype | Gene | Drug Use/Category/Class | Medical Field | Summary | Descriptive Sentence |
|---|---|---|---|---|---|---|
| gs309 | WT/WT | G6PD | Diabetes | Endocrinology | Normal Response Expected | You do not appear to carry any G6PD mutations linked to an unwanted side effect (hemolytic anemia). |
| gs307 | Carrier | G6PD | Diabetes | Endocrinology | Consider Alternatives | You carry a G6PD mutation that might lead to an unwanted side effect (hemolytic anemia) when taking glipizide; due to variable expression (i.e. in females), enzymatic testing for G6PD activity is advisable. |
| gs308 | G6PD-deficient | G6PD | Diabetes | Endocrinology | Consider Alternatives | You carry a G6PD mutation linked to an unwanted side effect (hemolytic anemia) when taking glipizide; non-sulfonylurea alternatives should be considered. |
